Our revenue to date has been generated through payments from our collaboration and license agreements, primarily from upfront and milestone payments and clinical trial cost sharing and expense reimbursement amounts.

filing / Aug 13, 2026 / receipt

Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its business objectives.

filing / Aug 13, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

filing / Aug 13, 2026 / receipt

Our revenue to date has been generated through payments from our collaboration and license agreements, primarily from upfront and milestone payments and clinical trial cost sharing and expense reimbursement amounts.

filing / May 7, 2026 / receipt

On July 2, 2025, we announced a workforce reduction of approximately 25% of current and planned roles, primarily in the areas supporting early-stage research and development and support functions following a strategic pipeline prioritization to focus on the development of 4D-150 and 4D-710.

filing / May 7, 2026 / receipt

In connection with the workforce reduction, the Company recorded total expense of $3.2 million including severance, benefits and related termination costs during the year ended December 31, 2025.

filing / May 7, 2026 / receipt

Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its business objectives.

filing / May 7, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

filing / May 7, 2026 / receipt

In-House Clinical Research Associate (Contract) | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4730940005", "remote": true, "category": "other", "function": "clinical", "location": "R

company_statement / Sep 10, 2026 / receipt

Clinical Trial Manager (Contract) | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4732954005", "remote": true, "category": "other", "function": "clinical", "location": "Emeryville, Cal

company_statement / Sep 10, 2026 / receipt

Research Associate, Formulation Development (Contract) | {"ats": "greenhouse", "city": "Emeryville", "state": "CA", "job_id": "4731936005", "remote": false, "category": "other", "function": "retail",

company_statement / Sep 9, 2026 / receipt

Associate Director, Clinical Operations | {"ats": "greenhouse", "city": null, "state": null, "job_id": "4728618005", "remote": true, "category": "other", "function": "operations", "location": "Remote,

company_statement / Aug 31, 2026 / receipt